News
FBRX
0.7182
-2.81%
-0.0208
Weekly Report: what happened at FBRX last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at FBRX last week (0408-0412)?
Weekly Report · 04/15 11:06
Forte Biosciences Price Target Announced at $2.75/Share by Ladenburg Thalmann
Dow Jones · 04/08 21:46
Forte Biosciences Raised to Buy From Neutral by Ladenburg Thalmann
Dow Jones · 04/08 21:46
Ladenburg Thalmann Upgrades Forte Biosciences to Buy, Announces $2.75 Price Target
Benzinga · 04/08 21:36
Weekly Report: what happened at FBRX last week (0401-0405)?
Weekly Report · 04/08 11:11
Buy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market Position
TipRanks · 04/08 10:45
Weekly Report: what happened at FBRX last week (0325-0329)?
Weekly Report · 04/01 11:09
What Makes Forte Biosciences (FBRX) a New Buy Stock
NASDAQ · 03/25 16:00
Weekly Report: what happened at FBRX last week (0318-0322)?
Weekly Report · 03/25 11:12
Forte Biosciences GAAP EPS of -$1.00
Forte Biosciences ended 2023 with approximately $37.1 million in cash and cash equivalents. The company expects to report a FY GAAP EPS of -$1.00 for the fiscal year ending March 18, 2024. Forte had 36.3 million shares of common stock outstanding as of December 31, 2023.
Seeking Alpha · 03/18 20:42
Forte Biosciences, Inc. Announces 2023 EPS $(1.00) Vs $(0.80) YoY
Research and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5.6 million during the same period in 2022. Forte ended 2023 with approximately $37.1 million in cash and cash equivalents. The company had approximately 36.3 million shares of common stock outstanding as of 2023.
Benzinga · 03/18 20:13
Press Release: Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update. The company is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The single ascending dose of the FB-102 phase 1 trial was successfully completed and dosing has begun in the multiple ascending dose cohorts.
Dow Jones · 03/18 20:05
Weekly Report: what happened at FBRX last week (0311-0315)?
Weekly Report · 03/18 11:10
Weekly Report: what happened at FBRX last week (0304-0308)?
Weekly Report · 03/11 11:07
Weekly Report: what happened at FBRX last week (0226-0301)?
Weekly Report · 03/04 11:10
Weekly Report: what happened at FBRX last week (0219-0223)?
Weekly Report · 02/26 11:23
Weekly Report: what happened at FBRX last week (0212-0216)?
Weekly Report · 02/19 11:24
Weekly Report: what happened at FBRX last week (0205-0209)?
Weekly Report · 02/12 11:14
Weekly Report: what happened at FBRX last week (0129-0202)?
Weekly Report · 02/05 11:22
More
Webull provides a variety of real-time FBRX stock news. You can receive the latest news about Forte Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBRX
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.